CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,580 enrolled
Drug / intervention
Intervention to address diffusion of responsibility +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05463705
NCT05463705N/ACompleted

Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications

Brigham and Women's Hospital·interventional·Posted Jul 19, 2022·Updated Nov 19, 2024

In Brief

A clinical study evaluating Intervention to address diffusion of responsibility and Intervention to address diffusion of responsibility + simplification of prescribing for Diabetes and 3 related conditions. Completed, enrolled 1,580 participants across 1 site.

Detailed Summary

This study will test the impact of addressing diffusion of responsibility with and without additional reduction of prescribing burden on SGLT-2i and GLP-1RAs prescribing compared to usual care. Population: MGH primary care physicians caring for at least 2 eligible patients. Eligible patients are individuals age18 years or older with type 2 diabetes and HbA1c \>7.5% and a compelling indication for an SGLT-2i or GLP-1RA (including cardiovascular disease, kidney disease, heart failure, or obesity), who are not already prescribed one of these therapies. Intervention: PCPs will be randomized to one of three arms: 1) intervention to address diffusion of responsibility, 2) Intervention to address diffusion of responsibility with additional simplification of prescribing, 3) usual care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 19, 2022
Enrollment StartMay 4, 2023
Primary CompletionNov 22, 2023
Study CompletionAug 22, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.0 years ago

Interventions

Intervention to address diffusion of responsibilitybehavioral

PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.

Intervention to address diffusion of responsibility + simplification of prescribingbehavioral

PCPs will receive the same contact addressing diffusion of responsibility as in the "Intervention to address diffusion of responsibility" arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by "routing" their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress.